Medico Remedies Limited (MEDICO) Fair Value & Analysis
Healthcare · IN · Market cap ₹3.4B
Fair value as of: Jul 3, 2026
From 15 valuation models · updated today
Share price −11.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹32.15 – ₹53.23 · fair‑value band ₹20.15 – ₹33.59 · the ₹40.41 price screens above the ₹26.87 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Medico Remedies Limited (MEDICO) currently trades at ₹40.41, while our model-based Fair Value estimate is ₹26.87 — implying the stock looks roughly 33.5% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Medico Remedies Limited generated revenue of ₹2.1B at a net margin of 6.4%. Revenue grew 37.5% year over year. It earns a return on equity of 19.0%. Net debt stands at ₹173M. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Medico Remedies Limited develops, manufactures, and sells pharmaceutical and nutraceutical products in India. The company offers antibiotics and anti-infectives; beta-lactams-penicillins and cephalosporins; antifungals; vitamins and supplements; cardiovascular products; antipyretic, analgesic, and NSAIDs medicines; antacid and anti-ulcer drugs; antidepressants, antipsychotics, and anti-epileptics; antimalarials; dry syrups; ointments and creams; anti-diabetics; syrups; and miscellaneous products, as well as diuretics, antireterovirals, and steroidal preparations. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Medico Remedies Limited reported revenue of ₹2.1B in FY2026 versus ₹1.2B in FY2022, a compound +14.3%/yr. Reported net income was ₹131M in FY2026, compounding +28.5%/yr from FY2022.
Is MEDICO fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Medico Remedies Limited (MEDICO) undervalued?
What is the fair value of MEDICO?
What is the quality score of MEDICO?
What is the revenue of Medico Remedies Limited (MEDICO)?
What is the net profit margin of MEDICO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.